Dechra Pharmaceuticals PLC (LSE : DPH) agreed to acquire Piedmont Animal Health LLC for approximately $210 million on July 20, 2022. Dechra raise approximately $215.827 million through the issue of 5,247,813 new ordinary shares of nominal value of 1 pence each in the capital of the Company representing approximately 4.8% per cent. Chris Treneman, Bruce Garrow and Daniel Adams of Investec Bank PLC will serve as financial adviser, sole broker and bookrunner to Dechra Pharmaceuticals PLC. J.P. Morgan acted as exclusive financial advisor to Piedmont Animal Health. Ernst & Young Global Limited acted as financial and Due Diligence Provider to Dechra Pharmaceuticals PLC.

Dechra Pharmaceuticals PLC (LSE:DPH) completed the acquisition of Piedmont Animal Health LLC for approximately $210 million on July, 2022.